Management of Cardio-renal Dysfunction | All About CPR & ACLS

Dear Dr. Renukaprasad A R, In 2021, the FDA authorized the innovative selective nonsteroidal mineralocorticoid receptor antagonist, finerenone, to reduce the risk of cardiorenal complications. In comparison to eplerenone and spironolactone, it has a greater binding capacity for mineralocorticoid receptors and has demonstrated efficacy in the therapy of cardiorenal disorders. In addition, it is well tolerated and has been demonstrated to have stronger cardiorenal effects than eplerenone. Significant advancements and modifications have been made to resuscitation techniques during the past 50 years. Moreover, there have been changes in recommendations for advanced cardiac life support (ACLS) based on several pieces of evidence and expert consensus. To gain detailed insights into "Finerenone for Cardiorenal Dysfunction | Updates on CPR and ACLS," join proficient Nephrologist Dr. Siddharth Mavani and Critical Care Specialist Dr. Bhagyesh Shah in our exclusive session, organized in association with CIMS, TODAY, 6:00 PM IST onwards Topics - Finerenone for Cardiorenal Dysfunction - Dr. Siddharth Mavani Updates on CPR and ACLS - Dr. Bhagyesh Shah Click to Join Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*